Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2005

View Archived Issues

Gene Logic and Roche sign drug repositioning and development agreement

MedImmune licenses Eph-targeting peptides from Burnham Institute

New phase II trial investigates satraplatin plus Taxol for advanced NSCLC

BPI: A BCL6 peptide inhibitor that reactivates p53 tumor suppressor

Lilly reviews pipeline progression

Valomaciclovir rights revert to Medivir

LU-AA24530 enters the clinic

Pain Therapeutics discontinues further development of PTI-901

Further clinical assessment of lacosamide

Xopenex HFA now available

Orphan drug designation for Cethrin

New phase IIa study of oral RSD-1235 to prevent recurrence of atrial fibrillation

Phase II study of Epadel for Alzheimer's dementia finishes early

Compounds with potential in the treatment of HIV infection disclosed

Recent patents of agents for cardiovascular disorders

Ambrisentan PAH study shows significant improvement in six-minute walk distance

New candidates for sickle cell disease

The antiepileptic seletracetam inhibits HVA Ca2+ currents and intracellular Ca2+ elevations

Zanolimumab active, well tolerated in CD4+ peripheral T-cell lymphoma

Evidence of activity seen with KOS-953-trastuzumab in metastatic breast cancer patients

GW and Almirall announce European development and marketing agreement for Sativex

Increlex MAA filed in Europe

Data on SB-715992 in advanced or metastatic breast cancer reported

E-7389 monotherapy demonstrates potential in refractory breast cancer

KOS-862 active in anthracycline- and taxane-resistant breast cancer

Tocosol Paclitaxel evaluated as first-line treatment of metastatic breast cancer

Glivec submitted in Europe for adult patients with Ph+ ALL

NDA submission for arformoterol for COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.